OpenAI President Greg Brockman has publicly discussed his personal journal entries during a trial. The lawsuit was filed by Elon Musk, who alleges that OpenAI abandoned its original nonprofit mission. Brockman testified that reading his personal journal in court was "very painful."
Brockman stated that his journal entries are deeply personal. He explained that they reflect a stream of consciousness, sometimes exploring alternative viewpoints. He also noted that he recorded text messages or Signal messages from others to consider their ideas. This process, he said, can make the entries appear self-contradictory or difficult to interpret out of context.
The journal contains approximately 100 pages of entries. Brockman began the journal in school and continued it to reflect on significant professional decisions. He maintained that the journal was never intended for public viewing.
Musk's legal team cited Brockman's journal entries in court filings. They allege these entries show a shift in OpenAI's focus from its nonprofit mission. One entry from 2017, for instance, discusses the idea of transitioning to a for-profit model. Brockman wrote, "Making the money for us sounds great and all."
Musk's attorney, Steven Molo, highlighted passages that he claims demonstrate Brockman's financial motivations. Brockman's stake in OpenAI is currently valued at approximately $30 billion. The journal entries cited in the trial span from 2015, when OpenAI was founded, to 2023.
Related stories
Nanoscale Redesign Boosts Superconductivity at Higher Temperatures
Researchers have found a way to boost superconductivity at higher temperatures and stronger magnetic fields by sculpting the substrate beneath the material.
AI Voice Cloning Technology Raises Persuasion and Fraud Concerns
New research shows AI can clone voices from short audio clips, increasing susceptibility to persuasion and raising concerns about potential fraudulent use.
COVID-19 Vaccines Continue to Protect Against Heart Problems
A large study found that updated COVID-19 vaccines continue to provide significant protection against cardiovascular disease, especially for older adults and those with underlying conditions.